RenovoRx Data Highlights Potential for Optimized Tumor Drug Delivery

Event summary

  • RenovoRx will present clinical data at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting on February 6, 2026.
  • The study, led by Christopher Laing, MD of Sutter Health, explores a simplified method for measuring intra-arterial pressure during TAMP procedures.
  • Data indicates a correlation between peak intra-arterial measurements and procedural variables like balloon spacing and vessel diameter.
  • RenovoRx generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025.
  • The IAG combination product (intra-arterial gemcitabine delivered via RenovoCath) has received Orphan Drug Designation for pancreatic and bile duct cancer.

The big picture

RenovoRx’s TAMP therapy platform represents a niche approach to targeted oncology, aiming to improve drug delivery and reduce systemic toxicity. The presented data suggests a refinement of the procedural technique, which could be crucial for demonstrating clinical efficacy and securing broader adoption. The company’s current focus on commercializing RenovoCath alongside the development of IAG highlights a dual-track strategy to generate revenue and advance its pipeline, but success hinges on demonstrating tangible clinical benefits and navigating the regulatory landscape.

What we're watching

Clinical Validation
The reproducibility of the simplified pressure measurement method will be critical for wider adoption and standardization of TAMP procedures, and the SIO presentation will provide initial insights.
Commercial Traction
Whether RenovoRx can sustain the momentum from the initial RenovoCath sales and expand adoption among National Cancer Institute-designated centers will determine the platform’s long-term viability.
Regulatory Pathway
The FDA’s evaluation of the IAG combination product under the 21 CFR 312 pathway will be a key indicator of the potential for broader regulatory approval and market access.

Related topics

Revenue Biotechnology